Douglas Galasko is a Neurology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9350 Campus Point Dr
Perlman Ambulatory Care Center - Neurology
La Jolla, CA 920371300
Telephone
858-657-8540Registry record last updated 15 Feb 2017.
Clinical trials
- Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
Sponsor: Preventive Medicine Research Institute
- Anti-Oxidant Treatment of Alzheimer's Disease
Sponsor: National Institute on Aging (NIA)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20233 payments
- GE HEALTHCAREProgram year20231 payment
- EISAI INC.Program year202212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Cholinesterase Inhibitor55.6%Donepezil Hcl64%Rivastigmine25%Galantamine Er12%Part D<11 patientsSSRI20.6%Sertraline Hcl68%Trazodone Hcl32%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
12 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:
- Amyloid clearing therapy in dementia with Lewy bodies plus Alzheimers disease (ACT DLB+)
Stanford University
FY2026$4,161,896U01NS145959 - In vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate safety of GSM-779690
University of California, San Diego
FY2026$1,744,718U01AG094588
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”